@betsmarr's 34-pound tirzepatide loss claim, fact-checked
Quick answer
The creator describes a 34-pound weight loss over approximately four months on tirzepatide, starting at 171 pounds and reaching 137, which is consistent with early-phase weight loss trajectories documented in the SURMOUNT-1 trial. She reports only next-day nausea and fatigue as side effects, which understates the adverse event profile documented in clinical trials and FDA labeling for tirzepatide. Her video also promotes a compounded tirzepatide platform, and viewers should understand that compounded formulations are not FDA-approved equivalents to Zepbound.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @betsmarr actually say?
The creator says she lost 34 pounds on tirzepatide over four months, dropping from 171 to 137 pounds. She describes her side effects as limited to "nausea and being tired only the day after the shot" and wraps up by directing viewers to a link in her bio with a discount code for a telehealth platform. That is the whole pitch: personal results, low downside, easy access.
She is clearly promoting a paid partnership with LifeRx.md, which matters for context. This is not a neutral testimonial. It is an affiliate arrangement, and viewers clicking her link help her earn money. The FTC requires this be disclosed clearly. A referral code and a platform tag in the caption is borderline disclosure at best.
Does the science back this up?
Her weight loss numbers are plausible and actually on the conservative side compared to trial data. Yes, the clinical evidence for tirzepatide is strong enough that downplaying it would be the bigger distortion.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on the highest dose of tirzepatide (15 mg) lost a mean of 20.9% of body weight over 72 weeks. If her starting weight was 171 pounds, a 34-pound loss over four months at approximately 20% body weight is at the faster end but not outside what trials documented in earlier months of treatment. The SURMOUNT-2 trial (Garvey et al., 2023, The Lancet) confirmed similar trajectories in people with obesity and type 2 diabetes. Four months is also roughly consistent with when patients hit meaningful weight loss milestones before the curve flattens.
What did they get wrong (or right)?
The side effect picture she paints is too clean, and that is a real problem. She says the "only symptoms are nausea and being tired only the day after the shot." That framing will mislead people.
SURMOUNT-1 reported that 4.3% of participants in the tirzepatide group discontinued due to adverse events, primarily gastrointestinal. Nausea affected roughly 30-40% of participants depending on dose, but vomiting, diarrhea, and constipation were also common. Pancreatitis, gallbladder disease, and heart rate increases are listed in the drug's labeling. None of that means tirzepatide is dangerous for everyone, but telling 245,000 viewers that side effects are just one tired day is genuinely irresponsible. It sets people up to either dismiss real symptoms or feel like something is wrong with them when they experience more than she did.
Her weight loss results and the four-month timeline, to her credit, are consistent with clinical data.
What should you actually know?
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA as Zepbound for chronic weight management in adults with obesity or overweight with a weight-related condition. The drug works. The clinical evidence is among the strongest produced for a weight-loss medication in decades.
But individual results vary considerably. Factors like baseline metabolic health, dose titration schedule, diet, and adherence all affect outcomes. The creator's results are real to her. They are not a guarantee or even a reliable benchmark for anyone else.
Compounded tirzepatide, which is what many telehealth platforms dispense, is not the same as FDA-approved Zepbound. The FDA has stated that compounded drugs are not proven to be safe and effective in the same way as their approved counterparts. Patients should ask their prescriber specifically what they are being dispensed and understand that difference before starting.
- Always disclose GLP-1 use to all your treating clinicians, not just the telehealth platform.
- Muscle loss is a documented concern with rapid weight loss on GLP-1 medications. Resistance training and adequate protein intake matter.
- Stopping the medication abruptly is associated with weight regain, as shown in the SURMOUNT-4 trial (Aronne et al., 2024, JAMA).
Should you trust this video?
Trust the basic weight loss claim as plausible. Do not trust the side effect claim as representative. And recognize that the person telling you this gets paid when you use her code. That does not make her experience fake, but it does make the framing a sales pitch, not medical advice. Talk to a licensed clinician who has access to your full health history before starting any GLP-1 therapy.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @betsmarr's 34-pound tirzepatide loss claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The creator describes a 34-pound weight loss over approximately four months on tirzepatide, starting at 171 pounds and reaching 137, which is consistent with early-phase weight loss trajectories documented in the SURMOUNT-1 trial.
FormBlends verdict
The creator describes a 34-pound weight loss over approximately four months on tirzepatide, starting at 171 pounds and reaching 137, which is consistent with early-phase weight loss trajectories documented in the SURMOUNT-1 trial. She reports only next-day nausea and fatigue as side effects, which understates the adverse event profile documented in clinical trials and FDA labeling for tirzepatide. Her video also promotes a compounded tirzepatide platform, and viewers should understand that compounded formulations are not FDA-approved equivalents to Zepbound.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes a 34-pound weight loss over approximately four months on tirzepatide, starting at 171 pounds and reaching 137, which is consistent with early-phase weight loss trajectories documented in the SURMOUNT-1 trial. She reports only next-day nausea and fatigue as side effects, which understates the adverse event profile documented in clinical trials and FDA labeling for tirzepatide. Her video also promotes a compounded tirzepatide platform, and viewers should understand that compounded formulations are not FDA-approved equivalents to Zepbound.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of up to 20.9% of body weight over 72 weeks on 15 mg tirzepatide, making the creator's results plausible but not typical.
- Tirzepatide's FDA label lists nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder disease, and pancreatitis as adverse events, not just next-day fatigue.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of up to 20.9% of body weight over 72 weeks on 15 mg tirzepatide, making the creator's results plausible but not typical.
- Tirzepatide's FDA label lists nausea, vomiting, diarrhea, constipation, abdominal pain, gallbladder disease, and pancreatitis as adverse events, not just next-day fatigue.
- SURMOUNT-4 (Aronne et al., 2024, JAMA) found that patients who stopped tirzepatide regained a significant portion of lost weight, meaning this is not a short-term fix.
- Compounded tirzepatide dispensed by telehealth platforms is not FDA-approved and has not been independently verified for potency, sterility, or equivalence to brand-name Zepbound.
- The creator earns a financial benefit when viewers use her code, which is a material conflict of interest that should be disclosed prominently under FTC guidelines.
- Muscle mass loss during GLP-1-assisted weight loss is a documented clinical concern. Resistance exercise and protein intake are recommended by obesity medicine specialists to mitigate it.
- Anyone considering tirzepatide should consult a licensed clinician with access to their full medical history, not base a decision on a 60-second social media testimonial.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Bets · TikTok creator
245.1K views on this video
Down 34 pounds on tirz 🥳 🔗 in my bio + use code bets for an extra $50 off @liferx.md #weightlossmotivation #weightloss #weightlossjouney #tirzepatidejourney
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Bets, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.